P
Poplar Therapeutics
Next-generation anti-IgE antibody therapy for atopic diseases
About Poplar Therapeutics
Poplar Therapeutics, Inc. is a clinical-stage immunology company that launched in January 2026, after previously being known as Phylaxis Bioscience. The company was founded by healthcare investor Tony Yao, M.D., Ph.D., who now serves as the Chief Scientific Officer. In January 2026, Poplar announced a $50 million Series A financing round led by SR One, Vida Ventures, and Platanus.
The company is focused on developing a new class of anti-IgE therapy to treat atopic conditions such as food allergies, asthma, and atopic dermatitis. Its lead program, PHB-050, is a next-generation anti-IgE antibody currently in Phase 1 clinical trials. PHB-050 features a unique triple-action mechanism designed to block IgE from binding to mast cells, rapidly reduce circulating IgE, and inhibit its production. This approach aims to address the needs of patients with highly elevated IgE levels who are often ineligible for or do not respond to first-generation therapies. The company's goal is to engineer the antibody to direct the IgE-drug complex to the liver for destruction, thereby driving total IgE levels toward zero.
The leadership team includes Chip Baird as President and CEO, who was appointed in October 2025 and previously served as CEO of 2seventy bio. Other key executives are René van der Merwe, M.D., as Chief Medical Officer and Vicki Eatwell as Chief Financial Officer. Poplar Therapeutics anticipates having results from its Phase 1 study in the second half of 2026 and has a cash runway through mid-2027.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2026 | $45M | $250M | SR One · RA Capital Management · ArrowMark Partners · Vida Ventures | ↗ |
| SERIES A✓Equity / VC | Jan 2026 | $50M | $200M | SR One · Vida Ventures · Platanus Ventures | ↗ |
Growth signals
Latest recorded traffic for Poplar Therapeutics is 1.6K monthly website visits, up 23.1% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Poplar Therapeutics in the Boston ecosystem
The Poplar Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
SR One
Vida Ventures
Platanus VenturesJanus Henderson Investors
RA Capital Management
ArrowMark Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Poplar Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Poplar Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








